FDA Moves to Ban Unapproved Fluoride Pills and Drops for Children, Citing Microbiome Risk and Outdated Science

The U.S. Food and Drug Administration (FDA) has announced a major policy shift, taking action to restrict the sale of unapproved ingestible fluoride prescription drug products intended for children. The agency has issued notices to four companies, outlining its intent to pursue enforcement against those marketing these unapproved drugs.

Key Restriction Targets

The FDA’s action focuses specifically on ingestible fluoride products (pills or drops) that are labeled for use in:

Children under age 3.
Older children at low or moderate risk for tooth decay.

Rationale for the Enforcement

The FDA emphasized that these products, despite being in use since the 1940s, have never been reviewed or approved for safety, effectiveness, or quality by the agency. The decision is based on a scientific evaluation that highlighted several concerns:

Risk to the Gut Microbiome: FDA Commissioner Marty Makary stated that while fluoride works to kill bacteria on teeth, “it may also alter the gut microbiome,” which is increasingly recognized as central to a child’s health and development.
Lack of Efficacy in Infants: A Cochrane review (a high-standard independent analysis) concluded that fluoride did not reduce dental caries (cavities) in baby teeth.
Preliminary Cognitive Risks: The agency also recognized “preliminary but potentially concerning data on risks,” including a recent meta-analysis that suggested increased fluoride exposure is associated with decreases in IQ.

Political and Policy Context

The enforcement action was politically charged, with Health and Human Services Secretary Robert F. Kennedy Jr. framing the action as “driving a stake through the heart of outdated science” and fulfilling President Trump’s commitment to the “Make Our Children Healthy Again Strategy” released by the Make American Healthy Again Commission.

FDA’s Path Forward

To support the policy change and guide clinical practice, the FDA has taken several parallel steps:

Warning to Professionals: A letter has been sent to health care professionals warning them about the risks associated with these unapproved products.
Research Agenda: The FDA, in partnership with the National Institutes of Health (NIH) and the U.S. Department of Health and Human Services (HHS), is launching a fluoride research agenda and the first national oral health strategy to close critical research gaps.

The agency’s message is that there are “better ways to protect children’s teeth” and that these unapproved ingestible products should not be used in children under 3 or by older children not deemed to be at high risk for tooth decay.